Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV

NCT04913272 is registered in ClinicalTrials.gov with Kibow Pharma as lead sponsor.

NCT NCT04913272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04913272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV
Lead sponsor
Kibow Pharma
Phase
Phase 2
Overall status
Suspended
Start date
June 24, 2021
Completion date
December 31, 2025
Enrollment
630 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease stage4